Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041483 | 0.92 | FAAH (0.59) | FAAHMAPK14TBK1IDO1TDO2 | |
| SCHEMBL16855862 | 0.82 | FAAH (0.58) | FAAH | |
| SCHEMBL17276352 | 0.82 | FAAH (0.58) | FAAH | |
| SCHEMBL3752475 | 0.81 | FAAH (0.70) | FAAHMAPK14TSHR | |
| SCHEMBL31570953 | 0.81 | PARP1 (0.58) | TBK1IDO1TDO2IDO2VEGFA | |
| SCHEMBL29979105 | 0.80 | MAPT (0.54) | TSHR | |
| SCHEMBL3044686 | 0.80 | GHSR (0.60) | MAPK14 | |
| SCHEMBL1226103 | 0.80 | MAPT (0.54) | TSHR | |
| SCHEMBL20765610 | 0.80 | FAAH (0.65) | FAAHMAPK14TSHR | |
| SCHEMBL30083799 | 0.79 | TBK1 (0.59) | TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017096045-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | FAAH 4430/4885MAPK14 205/4885TSHR 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.